Related Experiment Video
Updated: Jan 12, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
Treatment of Cutaneous Leishmaniasis with Liposomal Amphotericin B in the Elderly: A Randomized Clinical Trial
Samir F Azouz1,2,3, Ednaldo L Lago2, Luiz H Guimarães2,4,5
1Federal University of Bahia-Professor Edgard Santos University Hospital-Immunology Service, Salvador, Brazil.
Abstract:
The efficacy, best dosage, and safety of liposomal amphotericin B (LAB) in the treatment of cutaneous leishmaniasis (CL) caused by Leishmania braziliensis in elderly patients was determined by a randomized, controlled trial. We selected 28 patients of both sexes age 60 years old or older with CL diagnosis confirmed by detection of L. braziliensis DNA. The groups were treated with different total doses of LAB (group 1: 12 mg/kg; group 2: 18 mg/kg; and group 3: 24 mg/kg). Clinical and laboratory evaluations were carried out during a period of 180 days (day 0, day 15, day 30, day 60, day 90, and day 180). The highest cure rate (89%) was in group 3 (differences were not statistically significant) along with the lowest incidence of side effects (11%), suggesting that 24 mg/kg is the best dose of LAB to treat CL in elderly patients.
More Related Videos
12:22A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
Published on: December 30, 2012
06:57In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
Related Concept Videos
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion